Gloria Sura presents the key findings from a validation study of a targeted next-generation sequencing assay for the detection of genetic alterations in cerebrospinal fluid, as presented at the AMP 2026 Meeting & Expo. The study investigated whether sequencing might complement cytology in the confirmation of leptomeningeal disease in patients with cancer.
The following transcript has been edited for clarity.
Hello, my name is Gloria Sura. I'm an Assistant Professor of Pathology at the University of Texas MD Anderson Cancer Center, where I practice cytopathology and molecular genetic pathology.
I'm presenting the validation of a rapid targeted next-generation sequencing assay for somatic variant and gene fusion detection in cerebrospinal fluid.
So, for background, leptomeningeal disease in patients with cancer is diagnosed from a combination of clinical findings, imaging, and cerebrospinal fluid cytology. Cytology remains the only test that confirms leptomeningeal metastasis because it rests on the morphologic identification of tumor cells. However, a single lumbar puncture finds malignant cells in only about half of affected patients and cytology gives us no genotype to guide predictive therapy.
Liquid biopsy of plasma can't fill that gap alone because it underrepresents tumor in the central nervous system due to the blood–brain barrier. So, we extended a rapid amplicon-based panel, previously validated in plasma, to cell-free total nucleic acid from 3 millilitres of cerebrospinal fluid. It covers hotspot single nucleotide variants in indels and 45 genes, and fusions involving 18 genes.
In the validation, against patients’ prior plasma or tissue sequencing, the assay detected six of seven compared or reported alterations, made no cause and negative specimens, and met our prespecified acceptance criteria.
One practical finding for a pathologist – we found that spiking cerebrospinal fluid with 5 percent blood lowered the detected variant allele fractions up to 8.5-fold. So it may be better to skip sequencing in a bloody tab.
We then looked at the assay's first 8 months of clinical use, with 120 consecutive sequencing tests. At each lumbar puncture, about 12 to 14 milliliters of fluid was split, one portion to cytology and the other to the molecular lab. So every sequencing result has a cytological comparison from the same tab. Median turnaround was 2 days from specimen received to result report. Half of our evaluable tests were positive for a somatic mutation, and about 60 percent of detected somatic variants were classified as either tier 1 or tier 2 alterations per guidelines for the patient's cancer type.
Interestingly, sequencing and cytology detected tumor at similar rates, but often in different specimens. Sequencing found tumor DNA in 28 percent of available cytology negative specimens often at high allele fractions. Cytology, in turn, was abnormal including malignant suspicious or atypical classifications and 30 percent of sequencing negative specimens. But we found that this was mostly in cancers whose drivers lie outside of the panel's hotspots, and when cytology was malignant, sequencing returned a genotype in 79 percent of specimens.
The main limitation of the test was adequacy from DNA input. Forty-four percent of tests were canceled, predominantly because of poor coverage, and mostly in cytology-negative specimens. We found that the cytology-negative specimens had the same DNA input as cytology-abnormal ones but six-fold lower molecular coverage. So, for coverage quality, maybe DNA quality, and not only DNA input, determined whether or not the molecular coverage would be adequate for reliable reporting.
So, overall rapid cerebrospinal fluid sequencing complements cytology. It can add the most benefit when the tumor type carries panel covered drivers and when the clinical CNS genotype will change management with at least 3 milliliters of cerebrospinal fluid.
